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ABSTRACT
Introduction: Chronic kidney disease (CKD) is
common in patients with type 2 diabetes
(T2DM) and makes them particularly
susceptible to safety/tolerability issues related
to many classes of oral antihyperglycemic
agents (OAHA). Dipeptidyl peptidase-4
inhibitors (DPP-4is) like sitagliptin are
generally well tolerated in patients with T2DM
and renal disease and therefore may be
preferentially used in patients with CKD. To
assess the extent of this preference, the
characteristics of sitagliptin users with T2DM
and CKD were compared with those of other
(non-DPP-4i) OAHA users with T2DM and CKD.
Methods: Patients with T2DM and CKD with
claims between 2006 and 2012 were identified
from a United States insurance claims database.
Patients starting sitagliptin or another OAHA as
mono, dual, or triple therapy were compared.
Demographic and clinical characteristics within
5 years before starting or escalating to new
therapies were assessed.
Results: Compared to patients with CKD
starting other OAHAs, patients with CKD
starting sitagliptin as mono or dual therapy
were older, had more physician visits, were
more likely to have a history of heart failure and
to use loop diuretics. In triple therapy patients,
the differences between groups were not as
pronounced, but the overall prevalences of
comorbidities was higher.
Conclusion: Similar to prior observations in a
general T2DM population, patients with T2DM
and CKD prescribed sitagliptin tend to be older
and have more comorbidities than those
prescribed other classes of OAHA. If not
recognized and analyzed appropriately, this
channeling could lead to biased treatment
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INTRODUCTION
Chronic kidney disease (CKD) is a common
condition in patients with type 2 diabetes
(T2DM). An estimated 20–35% of patients
with T2DM have moderate to severe renal
impairment [1, 2]. However, many
antihyperglycemic medications are
contraindicated or need to be used with
caution in patients with CKD, complicating
T2DM treatment choices and management [3].
Patients with T2DM and CKD are particularly
susceptible to safety and tolerability issues
related to many classes of oral
antihyperglycemic agents (OAHA). Dipeptidyl
peptidase-4 inhibitors (DPP-4i) such as
sitagliptin are well tolerated in a broad range
of T2DM patient types, including those with
renal disease, and may therefore be
preferentially used in patients with CKD. Prior
studies have demonstrated the preferential use
of sitagliptin in several populations [4–7]. In
general, patients initiating treatment with
sitagliptin were older and had more
complications of diabetes and comorbidities
than patients initiating other
antihyperglycemic therapies [4–7]. If not
recognized and appropriately considered in the
analysis, this preferential selection of patients
with specific demographic and disease
characteristics for treatment with sitagliptin
(channeling bias) could lead to inaccurate
treatment effect estimates in comparative
analyses that include sitagliptin [8]. The
objective of this study was to describe the
baseline characteristics of patients with T2DM
and CKD initiating treatment with sitagliptin or
non-DPP-4i OAHAs to ascertain whether
channeling exists in this patient population.
METHODS
The Truven Health MarketScan Databases
(MarketScan, Truven Health Analytics, Ann
Arbor, MI, USA) contain medical claims
records for more than 150 million unique
patients dating from 1996. The records are
derived from outpatient and inpatient
insurance claims for employees of over 100
employers participating in more than 12 health
plans, and their beneficiaries in the United
States. Records consist of commercial claims
and healthcare encounters, including
information on demographics, health plan
membership, International Classification of
Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes, and Current Procedure
Terminology (CPT) codes. The records of
retirees with supplemental insurance are
included in the database thus providing data
on the elderly with continuity of care across
those\65 and C65 years of age.
Patients C25 years of age with T2DM and
CKD, with claims in the United States (US)
between January 2006 and June 2012, were
identified in MarketScan. Of these patients,
those initiating sitagliptin or a non-DPP-4i
OAHA were categorized by complexity of
antihyperglycemic treatment.
Patients were identified as having T2DM if
MarketScan records for the patient indicated at
least one inpatient or outpatient diagnosis of
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diabetes and at least one prescription for OAHA
medication.
Patients with CKD were identified by
ICD-9-CM diagnostic codes (585, 585.3, 585.4,
585.5, 585.6, 585.9, 403, 403.0, 403.00, 403.01,
403.1, 403.10, 403.11, 403.9, 403.90, 403.91,
250.4, 404, 404.0, 404.00, 404.01, 404.02,
404.03, 404.1, 404.10, 404.11, 404.12, 404.13,
404.9, 404.90, 404.91, 404.92, 404.93, 582,
582.0, 582.1, 582.2, 582.4, 582.8, 582.81,
582.89, 582.9).
Antihyperglycemic treatment was defined as:
(1) initiating monotherapy (C1 new outpatient
prescription record on or after the T2DM
diagnosis); (2) escalating to dual combination
therapy (C1 new prescription for a 2nd class
C90 days after the 1st class, with prescription
for 1st class overlapping the index date of 2nd
class); (3) escalating to triple combination
therapy (C1 new prescription for a 3rd class
C90 days after the 2nd class, with prescriptions
for 1st and 2nd classes overlapping the index
date of 3rd class).
Patients were required to have at least 1 year
of continuous enrollment in the database prior
to initiation/escalation of antihyperglycemic
treatment. Patients were excluded from the
analysis if they had a diagnosis of type 1
diabetes, ketoacidosis, malnutrition-associated
diabetes, drug-induced diabetes or gestational
diabetes without a subsequent T2DM diagnosis
code. Patients with ICD-9-CM codes explicit for
mild renal disease (stage 1 and 2) and patients
on insulin or other injectable therapy were also
excluded from the analysis.
Demographics, and clinical conditions and
health care resource utilization recorded up to
5 years before therapy initiation were assessed
as baseline characteristics. Over 70 clinical
conditions and comorbidities may have been
recorded in the database, including diabetes
complications, cancers, and cardiovascular
(CV), metabolic, gastrointestinal, hepatic,
infectious, psychiatric, pulmonary, and
neurological events. Types of health care
resource utilization recorded in the database
included physician and emergency department
visits, hospitalizations, days hospitalized, and
number of medications received.
Differences between sitagliptin and
non-DPP-4i OAHA treatment groups were
compared using absolute standardized
differences (ASD) [9]. ASD is the difference of
two means or proportions divided by the pooled
estimate of the standard deviation. Unlike the
traditional p value, ASD is a measure of
difference that is not influenced by large
sample sizes and has been demonstrated to be
a better measure of covariate balance [10, 12].
An ASD of at least 10% was used to indicate a
meaningful difference between treatment
groups [12].
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
A total of 35,922 patients with T2DM and CKD
were identified as meeting the inclusion criteria.
Over 45% of patients (46.7%; n = 16,742)
initiated sitagliptin (n = 1234) or a non-DPP-4i
OAHA monotherapy (n = 15,508), 40.5%
(n = 14,540) initiated an escalation to dual
combination therapy (sitagliptin, n = 2683;
OAHA, n = 11,857), and 12.9% (n = 4640)
initiated an escalation to triple combination
therapy (sitagliptin, n = 1385; OAHA,
n = 3255). Roughly, 15% of patients with
T2DM and CKD (14.8%; n = 5302) initiated
treatment with sitagliptin. In comparison, in
the patients excluded from this analysis due to a
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lack of recorded CKD, the percentage of patients
initiating sitagliptin was 7.4%.
The greatest differences between treatment
groups were observed in patients initiating
monotherapy or an escalation to dual
combination therapy. Compared to patients
initiating monotherapy with non-DPP-4i
OAHAs, patients initiating monotherapy with
sitagliptin were older (mean [standard deviation
(SD)]: sitagliptin 68.8 [12.5] years, non-DPP-4i
66.6 [12.8] years; ASD 17%), were more likely to
have a history of heart failure (Fig. 1a;
sitagliptin 23.0%, non-DPP-4i 18.6%; ASD
11%) or arrhythmia (Fig. 1a; sitagliptin 37.7%,
non-DPP-4i 31.7%; ASD 13%), were more likely
to use loop diuretics (Fig. 1a; sitagliptin 44.2%,
non-DPP-4i 38.0%; ASD 13%) or beta-blockers
(Fig. 1a; sitagliptin 66.3%, non-DPP-4i 61.3%;
ASD 11%), and had more physician visits
(Fig. 1b; mean [SD]: sitagliptin 73.2 [57.6]
physician visits, non-DPP-4i 66.3 [55.4]
physician visits; ASD 12%). The differences
between treatment groups (non-DPP-4i OAHA
users versus sitagliptin users) observed in
patients initiating an escalation to dual
therapy were similar to those observed in
patients initiating monotherapy, with the
exception that the between-group age
difference was not as great (mean [SD]:
sitagliptin 71.1 [11.1] years, non-DPP-4i
70.0 [11.0] years; ASD 10%) and the differences
for history of arrhythmia and use of
beta-blockers were not meaningful (Fig. 1c, d).
In patients initiating an escalation to triple
combination therapy, the differences between
treatment groups (non-DPP-4i OAHA users
versus sitagliptin users) were not as pronounced
as those seen in patients initiating monotherapy
or escalation to dual therapy, including the
between-group age difference (mean [SD]:
sitagliptin 68.9 [10.9] years, non-DPP-4i
68.4 [10.5] years; ASD 5%; Fig. 1e, f).
DISCUSSION
In this study of patients with T2DM from an
employee-based insurance database, sitagliptin
was initiated in a higher percentage of patients
with T2DM and CKD (14.8%) compared to
patients with T2DM but no record of CKD
(7.4%). Unlike many other OAHAs, sitagliptin is
approved for patients with any stage of renal
disease [11]. In light of this and its favorable
renal safety profile [12–15], the higher use of
sitagliptin in patients with CKD observed in the
current analysis is not surprising.
In general, patients with T2DM and CKD who
initiated treatment with sitagliptin tended to be
older and were more likely to have a
pre-treatment history of heart failure,
arrhythmia, or use of loop diuretics or
beta-blockers than patients initiating other
classes of OAHA. In this context, it is worth
noting the results of a large, recently completed
clinical trial examining the effects of
adding sitagliptin to usual care in patients with
T2DM and CV disease [16]. In the overall study
population, no difference in CV event rates
compared with placebo was observed (hazard
ratio [HR] for the primary composite CV
outcome was 0.98; 95% confidence interval
(CI): 0.88, 1.09; p\0.001 for noninferiority)
[16]. Additionally, in patient subgroups
evaluated by renal function, no difference in
CV risk was noted for patients with CKD
[estimated glomerular filtration rate (eGFR)
\60 mL/min/1.73 m2; HR= 0.92; 95% CI: 0.78,
1.10) or those without CKD (eGFR C60 mL/min/
1.73 m2; HR= 1.00; 95% CI: 0.89, 1.13) [16].
The most pronounced differences in baseline
characteristics between the treatment groups
were observed between patients initiating
monotherapy. As treatment complexity
increased, the differences in baseline
characteristics between treatment groups
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Fig. 1 Baseline characteristics of patients with type 2
diabetes and chronic renal disease up to 5 years before
initiating treatment with sitagliptin or non-DPP-4i oral
antihyperglycemic agent as monotherapy or as part of dual
or triple therapy. a, c, e Clinical conditions and comor-
bidities. b, d, f Health care resource utilization. ASD of
C10% indicates a meaningful difference between treatment
groups. For any between-group difference of ASD of at least
10%, the ASD value is in bold type. ASD absolute
standardized difference, CHF congestive heart failure,
DPP-4i dipeptidyl peptidase-4 inhibitor, Hosp hospital,
HTN hypertension, Meds medications, MI myocardial
infarction, Phys physician, TIA transient ischemic attack
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persisted but were attenuated, presumably due to
diminishing treatment options with increasing
treatment complexity. These observations of
channeling in patients receiving treatment with
sitagliptin are similar to those previously
reported in a general T2DM population [4–7].
While the MarketScan database includes
insurance claims data on a large, diverse
population from the US, these results may not
be generalizable to the overall US population or
to ex-US populations. In addition, the primary
uses of these data are for administrative
purposes, not research. Consequently, the
database has missing or limited data on a
number of important disease characteristics
and comorbidities. Importantly for this study,
patients with end-stage renal disease are likely
underrepresented since these patients are
Medicare eligible. Chronic renal disease was
defined solely through ICD-9-CM codes as
laboratory data are not available in our dataset.
CONCLUSIONS
This study further documents the presence of
channeling in patients initiating treatment with
sitagliptin. In this study, patients with CKD
initiating treatment with sitagliptin were
generally older and were more likely to have a
pre-treatment history of heart failure, arrhythmia,
or use of loop diuretics or beta-blockers than
patients initiating other classes of oral therapies.
If not recognized and analyzed appropriately, this
channeling could lead to biased treatment effect
estimates in comparative analyses, including
those involving users of sitagliptin.
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